Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

被引：4
|
作者：
John, Nevin [1 ]
Carroll, Antonia [2 ]
Brownlee, Wallace J. [2 ,3 ]
Chataway, Jeremy [1 ,2 ]
机构：
[1] UCL, Inst Neurol, Neuroinflammat, London WC1N 3BG, England
[2] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England
[3] Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat, London, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷 / 12期
关键词：
FINGOLIMOD;
D O I：
10.1136/jnnp-2019-320687
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1376 / +
页数：3
相关论文
共 50 条
  • [31] Natalizumab (Tysabri) treatment for relapsing multiple sclerosis
    Johnson, Kenneth P.
    NEUROLOGIST, 2007, 13 (04) : 182 - 187
  • [32] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [33] Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
    Syed, Yahiya Y.
    DRUGS, 2021, 81 (01) : 157 - 168
  • [34] Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
    Yahiya Y. Syed
    Drugs, 2021, 81 : 157 - 168
  • [35] Natalizumab for relapsing multiple sclerosis - The editorialist replies
    Ropper, AH
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2389 - 2389
  • [36] Natalizumab reduces loss of visual function in patients with relapsing multiple sclerosis
    Balcer, L
    Galetta, SL
    O'Connor, PW
    Havrdova, E
    Hutchinson, M
    Kappos, L
    Miller, DH
    Phillips, JT
    Polman, CH
    Stuart, WH
    Calabresi, PA
    Confavreux, C
    Radue, EW
    Rudick, RA
    Lublin, FD
    Giovannoni, G
    Wajgt, A
    Weinstock-Guttman, B
    Wynn, DR
    Lynn, FA
    Panzara, MA
    Sandrock, AW
    NEUROLOGY, 2006, 66 (05) : A251 - A251
  • [37] Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis
    Fox, E. J.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Lake, S. L.
    Margolin, D. H.
    Oyuela, P.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 465 - 466
  • [38] The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM
    Havrdova, E
    O'Connor, P
    Hutchinson, M
    Kappos, L
    Miller, D
    Phillips, JT
    Polman, C
    Lublin, F
    Giovannoni, G
    Wajgt, A
    Lynn, F
    Toal, M
    Panzara, M
    Sandrock, A
    JOURNAL OF NEUROLOGY, 2005, 252 : 46 - 46
  • [39] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
  • [40] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
12345